GeoVax to Discuss BARDA Contract Termination at Emerging Growth Conference

GeoVax Labs, Inc., a clinical-stage biotechnology company developing vaccines and immunotherapies, will present at the Emerging Growth Conference on April 16, 2025, with a focus on the recent termination of its BARDA contract for the GEO-CM04S1 COVID-19 vaccine program.

During the live, interactive online event, Chairman and CEO David Dodd will offer stakeholders a comprehensive overview of the company's current strategic position following the contract termination. The presentation, scheduled for 3:40 pm ET, represents a critical opportunity for investors and the broader healthcare investment community to gain direct insights into the company's future direction.

The GEO-CM04S1 program has been exploring innovative approaches to COVID-19 vaccination, particularly targeting immunocompromised patients and populations for whom existing vaccines have shown limited efficacy. The BARDA contract termination could potentially signal significant implications for the company's research and development trajectory in the infectious disease space.

GeoVax's clinical pipeline extends beyond COVID-19, including an oncolytic solid tumor gene-directed therapy called Gedeptin® and a vaccine targeting Mpox and smallpox. The conference presentation may provide clarity on how the company plans to allocate resources and maintain its research momentum following the contract's conclusion.

Investors and interested parties will have an opportunity to submit questions in advance or during the live event, enabling direct engagement with the company's leadership about its strategic outlook and ongoing research initiatives.